CHILDREN'S TYLENOL PLUS COLD OTC
Generic Name and Formulations:
Acetaminophen 160mg, chlorpheniramine maleate 1mg, phenylephrine HCl 2.5mg; per 5mL; liq; grape flavor.
McNeil Consumer Healthcare
Indications for CHILDREN'S TYLENOL PLUS COLD:
Nasal congestion, rhinorrhea, sore throat, fever, headache, minor aches and pains.
<4yrs (<36lbs): do not use. 4–5yrs (36–47lbs): not recommended. 6–11yrs (48–95lbs): 10mL every 4 hours as needed; max 5 doses/24 hours.
Children <4yrs old (<36lbs). During or within 14 days of MAOIs. Concomitant other acetaminophen products. For use as a sedative hypnotic.
Hepatic dysfunction. Cardiovascular disease. Hypertension. Thyroid disease. Glaucoma. Diabetes. Asthma. Lower respiratory disorders.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers increase pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants.
Analgesic + antihistamine + sympathomimetic.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability, hepatotoxicity (overdosage).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|